LFS is caused by heterozygous pathogenic variants in TP53, as established by ClinGen DEFINITIVE gene-disease validity classification. The p53 protein functions as a sequence-specific transcription factor that integrates cellular stress signals including DNA strand breaks, oncogene activation, and hypoxia, and initiates downstream programs of cell cycle arrest, apoptosis, and DNA repair. Germline loss-of-function variants leave cells with a single functional TP53 allele; somatic loss of the remaining allele, occurring in susceptible tissues, eliminates tumor suppressive capacity and precipitates malignant transformation. ClinVar documents a broad range of pathogenic variant types in TP53, including missense variants disrupting the DNA-binding domain and truncating variants. Autosomal dominant inheritance is documented, with a pathogenic variant in one parent conferring a 50% transmission probability to offspring.

According to GeneReviews, consensus clinical diagnostic criteria for Li-Fraumeni syndrome have been published. Clinical suspicion is guided by modified Chompret criteria, which incorporate tumor type, age of onset, and family history — including indicators such as premenopausal breast cancer, soft-tissue sarcoma, or a personal history of multiple primary LFS-spectrum tumors. Molecular genetic testing of TP53 is used to confirm the diagnosis, including sequence analysis and deletion/duplication studies. Tumor immunohistochemistry for p53 protein expression abnormalities may provide supportive evidence in tumor specimens. No newborn screening panel inclusion for LFS is documented in this packet. GeneReviews notes that newborn screening for the TP53 founder variant has been explored in Brazil given its regionally elevated prevalence.

Pazopanib (Votrient) holds FDA approval for the treatment of soft tissue sarcomas and is documented as an approved agent in this packet's orphan drug records, relevant to a core LFS tumor type. Liposomal vinorelbine holds FDA orphan drug designation for soft tissue carcinoma treatment but carries designation status only and is not an approved therapy. No approved treatments specific to LFS as a syndrome — rather than to its individual tumor manifestations — are documented in this packet. According to GeneReviews, clinical practice guidelines for LFS have been published addressing the management of this condition. GeneReviews further documents that published literature identifies ionizing radiation, tobacco use, and unprotected sun exposure as factors associated with elevated carcinogenic risk in this population, a consideration reflected in LFS clinical guidelines. No patient assistance programs are documented in this packet.

At a population level, GeneReviews documents that the risk of any cancer by age 50 years was 92.4% in women and 59.7% in men in a large international LFS cohort. The five core LFS-associated tumor types — adrenocortical carcinoma, breast cancer, CNS tumors, osteosarcoma, and soft-tissue sarcoma — differ substantially in their natural histories and treatment-response profiles; aggregate risk data reflect this heterogeneous mixture. GeneReviews documents that surveillance protocols have been developed with the goal of earlier-stage cancer detection in this population. Detailed natural history data with outcomes by tumor type are not separately certified in this packet beyond the cancer risk estimates sourced from GeneReviews.

Thirteen active clinical trial records are documented for Li-Fraumeni syndrome on ClinicalTrials.gov. Among the documented trials, studies include a longitudinal natural history and genetic study at the National Cancer Institute (NCT01443468, recruiting), eligibility screening surveys through the NCI Clinical Genetics Branch (NCT07005297), and familial childhood cancer predisposition investigations at St. Jude Children's Research Hospital. A research landscape of 178 classified publications is documented, with reviews and meta-analyses as the dominant publication type alongside 34 case reports and articles addressing gene therapy and biomarker approaches. Active clinical trials for this condition are listed on ClinicalTrials.gov.